Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06281678 · ClinicalTrials.gov registry record · Phase 2

A Study of IBI363 in Subjects with Advanced Solid Malignancies

A Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Innovent Biologics (Suzhou) Co..

Recruiting
Registry status
Phase 2
Development phase
178
Enrollment target
9
Study locations

NCT06281678: Recruiting Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Innovent Biologics (Suzhou) Co..

NCT06281678 is a Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 178 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06281678, a Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Innovent Biologics (Suzhou) Co..

RECRUITING
Registry status
Phase 2
Development phase
178 participants
Enrollment target
9
Study locations

Study Summary

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

Interventions

  • DRUG IBI363

Study Locations (9)

Florida

  • Ocala Oncology Center - Ocala
  • BRCR Medical Center - Plantation

Michigan

  • Michigan Hematology & Oncology Consultants - MedOnc Dearborn - Dearborn
  • Michigan Hematology & Oncology Consultants - MedOnc Troy - Troy

Texas

  • MD Anderson Cancer Center-University of Texas - Houston
  • Oncology Consultants P.A. - Houston

California

  • University of California, San Francisco (UCSF) - San Francisco

Kansas

  • University of Kansas Medical Center (KUMC) - Fairway

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2024-04-08
Est. Completion 2026-12-31
Phase Phase 2
Innovent Biologics (Suzhou) Co.

7 total trials

What NCT06281678 shows while recruiting

NCT06281678 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower).

The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which IBI363 is the first listed.

NCT06281678 lists 9 locations in 6 states (Florida, Michigan, Texas).

Frequently Asked Questions

What is clinical trial NCT06281678 about?

NCT06281678 is a clinical study titled "A Study of IBI363 in Subjects with Advanced Solid Malignancies". This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

What is the current status of trial NCT06281678?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2024-04-08. Estimated completion is 2026-12-31.

What conditions does trial NCT06281678 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Renal Cell Cancer.

What interventions are being tested in trial NCT06281678?

The interventions under investigation include: IBI363 (DRUG).

Who is sponsoring clinical trial NCT06281678?

This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06281678 being conducted?

This trial has 9 study locations across California, Florida, Kansas, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06281678's enrollment target sits among peer trials

178 181st of 454 higher than 274 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03642002 · 178 participants · NA

    The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

  • NCT04227847 · 178 participants · Phase 1

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  • NCT04855214 · 178 participants

    Evaluating the Experience of Upper Limb Prosthesis Use

  • NCT05391126 · 178 participants · NA

    GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06281678, the US trial registry maintained by the National Library of Medicine. NCT06281678 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.